Your browser doesn't support javascript.
loading
Clinical evaluation of an application aid for less-invasive surfactant administration (LISA).
Maiwald, Christian Achim; Neuberger, Patrick; Franz, Axel R; Engel, Corinna; Vochem, Matthias; Poets, Christian F.
Afiliación
  • Maiwald CA; Department of Neonatology, University Children's Hospital Tubingen, Tubingen, Germany Christian.Maiwald@med.uni-tuebingen.de.
  • Neuberger P; Center for Pediatric Clinical Studies (CPCS), University Children's Hospital Tubingen, Tubingen, Germany.
  • Franz AR; Department of Neonatology, Klinikum Stuttgart Olgahospital Frauenklinik, Stuttgart, Germany.
  • Engel C; Department of Neonatology, University Children's Hospital Tubingen, Tubingen, Germany.
  • Vochem M; Center for Pediatric Clinical Studies (CPCS), University Children's Hospital Tubingen, Tubingen, Germany.
  • Poets CF; Center for Pediatric Clinical Studies (CPCS), University Children's Hospital Tubingen, Tubingen, Germany.
Arch Dis Child Fetal Neonatal Ed ; 106(2): 211-214, 2021 Mar.
Article en En | MEDLINE | ID: mdl-33023914
ABSTRACT

BACKGROUND:

Less-invasive surfactant administration (LISA) is increasingly used. We investigated the feasibility of a new LISA-device (Neofact®) in neonates.

DESIGN:

Prospective observational pilot study with open-label LISA in two tertiary neonatal intensive care units. PATIENTS 20 infants with a gestational age of ≥26+0/7 weeks and an indication for LISA (Respiratory Severity Score (RSS)≥5 or fraction of inspired oxygen (FiO2) ≥0.30). Infants with respiratory tract malformations or unavailability of an instructed neonatologist were excluded. MAIN OUTCOME

MEASURES:

Success of LISA, defined as laryngoscopy-confirmed intratracheal catheter position or a decrease in FiO2 by ≥0.05 or to 0.21, accompanied by an RSS decrease of ≥2; number of attempts needed for tracheal catheterisation.

RESULTS:

20/57 screened infants were enrolled. Successful application occurred in 19/20 (95%). One application failed after three attempts. No device-related adverse events occurred. The median number of attempts was 2, success rate per attempt 19/31 (61%).

CONCLUSION:

LISA via Neofact® appears feasible.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndrome de Dificultad Respiratoria del Recién Nacido / Surfactantes Pulmonares Tipo de estudio: Observational_studies Límite: Humans / Newborn Idioma: En Revista: Arch Dis Child Fetal Neonatal Ed Asunto de la revista: PEDIATRIA / PERINATOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Síndrome de Dificultad Respiratoria del Recién Nacido / Surfactantes Pulmonares Tipo de estudio: Observational_studies Límite: Humans / Newborn Idioma: En Revista: Arch Dis Child Fetal Neonatal Ed Asunto de la revista: PEDIATRIA / PERINATOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Alemania